Company / Gross Profit
Boston Scientific Gross Profit History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Profit
$13.9B
FY2025
5-year range
$7.6B / $13.9B
FY2021-FY2025
Trend
+20.6%
vs FY2024
Sector context
#3 of 100
Health Care
What the data says
Among 100 Health Care companies, Boston Scientific is in the top 3% for gross profit. Gross Profit has increased for 5 consecutive years, from $7.0B in FY2020 to $13.9B in FY2025.
Based on SEC 10-K filings.
$13.9B in FY2025 with a 5-year CAGR of +14.6%. Ranks 3rd among 100 companies in Health Care.
Improved from $9.9B to $13.9B over the past 2 years.
Health Care sector context is included.
Gross Profit over time
Growth rates
- 3-Year CAGR
- +16.7%
- 5-Year CAGR
- +14.6%
- 10-Year CAGR
- -
Sector benchmark
Top 3% in Health CareTop 3% of 100This company $13.9B Sector average $1.8B
▼
+662.4% above sector average
Key checks
Key Insights
- Boston Scientific's gross profit has grown for 5 consecutive years.
- 5-year CAGR of +14.6%, indicating consistent growth.
- In FY2025, gross profit increased 20.6% year-over-year.
- Ranks #3 out of 100 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross ProfitValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $13.9B | +20.6% |
| FY2024 | $11.5B | +16.1% |
| FY2023 | $9.9B | +13.4% |
| FY2022 | $8.7B | +14.5% |
| FY2021 | $7.6B | +8.7% |
| FY2020 | $7.0B | -8.0% |
| FY2019 | $7.6B | +8.7% |
| FY2018 | $7.0B | +8.6% |
| FY2017 | $6.5B | +8.3% |
| FY2016 | $6.0B | +12.4% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026